Clinical Trial: NCT06015503
A Phase Ⅱ Study Assessing the Safety and Efficacy of PLB1004 in EGFR ex20ins Mutation Patients With Advanced and Metastatic Non-small Cell Lung Cancer(NSCLC)
Status:
ACTIVE NOT RECRUITINGPhase:
Phase 2| Lead Sponsor: | Avistone Biotechnology Co., Ltd. |
| Information Provided By: | Avistone Biotechnology Co., Ltd. |
| Last Update Posted: | 2026-05-22 |
Study Overview
Brief Summary
It is a phase Ⅱ,open-label, single-line, Multiple cohorts, Multicenter study assessing the Safety and Efficacy of PLB1004 in EGFR ex20ins mutation patients with Advanced and Metastatic Non-small Cell Lung Cancer(NSCLC).
Official Title
A Phase Ⅱ,Open-label, Single-line, Multiple Cohorts, Multicenter Study Assessing the Safety and Efficacy of PLB1004 in EGFR ex20ins Mutation Patients With Advanced and Metastatic Non-small Cell Lung Cancer(NSCLC)
Conditions
NSCLC (Non-small Cell Lung Cancer)
Intervention / Treatment
- Drug: PLB1004
Other Study ID Numbers
- PLB1004-II-01
Start Date (Actual)
2023-07-21
Primary Completion Date (Actual)
2025-03-06
Study Completion Date (Estimated)
2026-12-30
Enrollment (Estimated)
139
Study Type
Interventional
Phase
Phase 2
| Lead Sponsor: | Avistone Biotechnology Co., Ltd. |
| Information Provided By: | Avistone Biotechnology Co., Ltd. |
| Last Update Posted: | 2026-05-22 |
Study Overview
Brief Summary
It is a phase Ⅱ,open-label, single-line, Multiple cohorts, Multicenter study assessing the Safety and Efficacy of PLB1004 in EGFR ex20ins mutation patients with Advanced and Metastatic Non-small Cell Lung Cancer(NSCLC).
Official Title
A Phase Ⅱ,Open-label, Single-line, Multiple Cohorts, Multicenter Study Assessing the Safety and Efficacy of PLB1004 in EGFR ex20ins Mutation Patients With Advanced and Metastatic Non-small Cell Lung Cancer(NSCLC)
Conditions
NSCLC (Non-small Cell Lung Cancer)
Intervention / Treatment
- Drug: PLB1004
Other Study ID Numbers
- PLB1004-II-01
Start Date (Actual)
2023-07-21
Primary Completion Date (Actual)
2025-03-06
Study Completion Date (Estimated)
2026-12-30
Enrollment (Estimated)
139
Study Type
Interventional
Phase
Phase 2